GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Cyclically Adjusted Revenue per Share

Novartis AG (BUE:NVS) Cyclically Adjusted Revenue per Share : ARS7,901.77 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Novartis AG Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novartis AG's adjusted revenue per share for the three months ended in Mar. 2025 was ARS14,673.495. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS7,901.77 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novartis AG's average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novartis AG was 4.30% per year. The lowest was -0.90% per year. And the median was 1.20% per year.

As of today (2025-05-20), Novartis AG's current stock price is ARS32200.00. Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ARS7,901.77. Novartis AG's Cyclically Adjusted PS Ratio of today is 4.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis AG was 4.87. The lowest was 2.83. And the median was 3.80.


Novartis AG Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Revenue per Share Chart

Novartis AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 836.85 1,128.34 1,957.19 5,877.91 6,856.03

Novartis AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,230.66 7,855.15 7,599.51 6,856.03 7,901.77

Competitive Comparison of Novartis AG's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.


;
;

Novartis AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=14673.495/107.7224*107.7224
=14,673.495

Current CPI (Mar. 2025) = 107.7224.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 95.618 100.464 102.527
201509 96.298 99.785 103.958
201512 136.960 99.386 148.448
201603 143.848 99.475 155.774
201606 147.646 100.088 158.908
201609 153.342 99.604 165.840
201612 166.948 99.380 180.963
201703 152.105 100.040 163.786
201706 173.621 100.285 186.497
201709 188.561 100.254 202.609
201712 104.144 100.213 111.948
201803 191.669 100.836 204.759
201806 247.763 101.435 263.120
201809 358.420 101.246 381.349
201812 383.235 100.906 409.123
201903 382.878 101.571 406.067
201906 460.540 102.044 486.168
201909 607.809 101.396 645.734
201912 658.935 101.063 702.353
202003 688.287 101.048 733.753
202006 690.662 100.743 738.510
202009 808.706 100.585 866.094
202012 928.530 100.241 997.833
202103 1,009.691 100.800 1,079.033
202106 1,115.448 101.352 1,185.557
202109 1,159.738 101.533 1,230.441
202112 413.356 101.776 437.509
202203 1,230.099 103.205 1,283.942
202206 1,424.259 104.783 1,464.215
202209 1,374.585 104.835 1,412.447
202212 1,703.846 104.666 1,753.597
202303 2,058.807 106.245 2,087.442
202306 2,690.978 106.576 2,719.937
202309 4,078.646 106.570 4,122.770
202312 4,099.456 106.461 4,148.020
202403 9,932.977 107.355 9,966.980
202406 11,267.718 107.991 11,239.703
202409 12,353.217 107.468 12,382.471
202412 13,639.024 107.128 13,714.687
202503 14,673.495 107.722 14,673.495

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Novartis AG  (BUE:NVS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32200.00/7901.77
=4.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novartis AG was 4.87. The lowest was 2.83. And the median was 3.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novartis AG Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Cyclically Adjusted Revenue per Share
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.